SMS Pharmaceuticals Ltd Q1 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/qmrbdj4d8gudik3vx61vy0bw.pdf

Key Takeaways


Margin Recovery & Backward Integration

Potluri: "See when my selling price remains same and even might depreciate a little also based on the current market scenario. But still we are able to achieve those margins, trying to see what best we can do by backward integrating."

Revenue Drivers & Product Segments


Capacity & Pipeline


Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growthAchieve 20% growth in FY25FY25
EBITDA marginAchieve 20% EBITDA margin, driven by backward integrationFY25
Backward integration completionComplete backward integration of key intermediatesH1 FY25
Capacity expansionIncrease production capacityEnd of Q4 FY25
Capacity utilizationCross ~80% utilization rate (from ~70%)End of FY25
Ibuprofen cost positionBecome one of the most cost-competitive products in the marketNext 1-2 quarters
New product launchesLaunch 8 to 10 products in existing therapiesNext 12-18 months
Annual growth floorGrow by a minimum of 20% year-on-yearOngoing
Potluri: "definitely I think year-on-year our target is to improve at least a minimum of 20% to 25%. So, that is what we have done last year to this year, and I think going forward that is our target, at least grow by a minimum of 20% year-on-year."

Key Metrics

MetricQ1 FY25
Revenue from operations₹164.45 cr, +22% YoY and -33% QoQ due to seasonality
Gross margin35%, up YoY and QoQ, attributed to lower raw material prices and improved product mix
PAT₹16.48 cr, +76% YoY, driven by higher EBITDA and lower financial costs
PAT margin10%, compared to 7% in Q1 FY24
FY25 revenue growth guidance20%, reiterated by management
FY25 EBITDA margin guidance20%, reiterated by management
Previous year EBITDA margin17%, FY24 full year
Ibuprofen volume~350 tons per month, up from 150-200 tons range previously
Capacity utilization~70%, anticipated to cross ~80% by end of FY25
CAPEX plan₹150 cr, ~70% for backward integration and ~30% for capacity expansion
Products backward integrated to KSM stage5-6 products, out of ~35 total products
Anti-diabetic market share in EuropeOver 50%, for one anti-diabetic product
Vizag facility capacity~4,000 kiloliters, of which ~1,000-1,500 kiloliters is ibuprofen
Backward integration stages for Sitagliptin8 stages in-house, up from 2 stages previously